Research Article

High Prevalence of Arcobacter Carriage in Older Subjects with Type 2 Diabetes

Maria Teresa Fera,1 Giuseppina T. Russo,2 Antonino Di Benedetto,2 Erminia La Camera,1 Angelo Orlando,2 Annalisa Giandalia,2 Vincenzo F. Ruffa,2 Giulia Lanza,2 Valeria Lentini,3 Giuseppa Perdichizzi,2 and Domenico Cucinotta2

1 Department of Pathology and Experimental Microbiology, University of Messina, 98125 Messina, Italy
2 Department of Internal Medicine, University of Messina, 98125 Messina, Italy
3 Department of Animal Biology and Marine Ecology, University of Messina, 98166 Messina, Italy

Correspondence should be addressed to Maria Teresa Fera, mtfera@unime.it

Received 31 January 2010; Accepted 25 March 2010

Academic Editor: Schwan William

Copyright © 2010 Maria Teresa Fera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Arcobacters are potential pathogens related to diarrheic infections and, rarely, septicaemia. This study evaluated the prevalence of arcobacters in stool samples of subjects with (n = 38) and without (n = 61) type 2 diabetes by using cultural and molecular techniques. Three Arcobacter positive cultures were found, all among diabetic subjects, whereas molecular analysis showed a carriage rate of 79% and 26.2% in subjects with and without type 2 diabetes (P < .001), respectively. The multivariate analysis showed that type 2 diabetes (β = 1.913; 95%CI: 2.378–19.285; P < .0001) and age (β = 1.744; 95%CI: 2.077–15.766; P = .001) were the only factors independently associated with arcobacters colonization in this population. Our study demonstrated a high prevalence of arcobacters colonization in type 2 diabetic and older subjects. The clinical significance and the potential health risk associated with these emerging species remain to be determined.

1. Introduction

The genus Arcobacter currently includes ten species. Pathogenic strains belonging to Arcobacter butzleri, Arcobacter cryaerophilus, and Arcobacter skirrowii have been isolated from human specimens, as well as from animal faeces and food of animal origin [1–6]. Arcobacter nitrofigilis, Arcobacter halophilus, as well as a number of recently published species such as Arcobacter cibarius, Arcobacter marinus, Arcobacter thereiu, and Arcobacter mytilii, and the not yet established species candidatus A. sulfidicus have been isolated from a variety of sources, but not from humans yet [7–13].

Epidemiological data on arcobacters colonization in humans are limited [1, 14, 15]; overall, the presence of these potential pathogens seems to be generally low and seldom associated with gastrointestinal disorders. Thus, A. butzleri, A. cryaerophilus, and A. skirrowii have been mainly isolated from stool specimens from patients with diarrhoea and in some cases of septicemia [1–3, 16–20].

Most infections are believed to result from the ingestion of contaminated food or water [21, 22], and the ubiquitous environmental distribution of arcobacters may be related to the high occurrence of these microorganisms in animal faecal samples [4, 23].

Diabetic subjects seem to be particularly prone to colonization by members of the Campylobacter family like Helicobacter pylori [24, 25]. However, to date, there are no data on carriage rate in this type of patients by Arcobacter, another genus of this family.

In this study we investigated arcobacters carriage rates and the clinical characteristics of a group of subjects with and without type 2 diabetes and with no sign or symptom for gastrointestinal disorders.

2. Materials and Methods

2.1. Subjects. A group of nonhospitalized subjects with (n = 38) and without (n = 61) type 2 diabetes, without any
sign or symptom for gastrointestinal disorders, consecutively attending the outpatient clinic for Metabolic disorders of the Department of Internal Medicine of Messina University, Italy, were recruited into this study. All study subjects gave their informed consent and the study was approved by the local ethical committee.

Lifestyle (socio-economical status, smoking) and clinical data were collected from all participants through a standardized questionnaire. Type 2 diabetes was diagnosed according to ADA 1997 criteria [26], and all diabetic participants were currently treated with diet, oral agents, insulin, or a combination of them. Data on retinopathy, neuropathy, and nephropathy, as diagnosed according to ADA 2008 guidelines [27], as well as data on macrovascular disease, as defined as a composite end-point [28, 29] including documented myocardial infarction, ischaemic heart disease, coronary heart bypass, coronary angioplasty, cerebral thromboembolism and peripheral amputations were also available for diabetic subjects only.

2.2. Clinical and Laboratory Measurements. An accurate physical examination was performed in each participant. Weight, height, body mass index (BMI), waist circumference and blood pressure, were also measured according to standard procedures.

Fasting blood samples were collected from all the participants for measurements of the study parameters. Fasting plasma glucose, lipid concentrations, as well as leucocyte blood count and erythrocyte sedimentation rate (ESR) were measured with standard laboratory methods. Glycated haemoglobin (HbA1c) was measured using an automated high-performance liquid chromatography analyzer (Diamat; Bio-Rad Laboratories, Milan, Italy) in diabetic participants, only; normal range values were 4–6%.

2.3. Specimen Collection. Stool samples from all participants were collected and readily sent to the laboratory for subsequent analyses. On arrival in the laboratory, samples were kept under cooled conditions until culture, which was usually performed within 1 to 3 h of receipt.

2.4. Cultural Methods. For the isolation of Arcobacter spp., direct plating and enrichment procedures [30] were applied to faecal samples emulsioned in approximately 1 g/mL of sterile saline.

2.5. Molecular Methods. PCR assay was performed to confirm presumptive isolates and was directly on DNA extracted from stool samples, according to the manufacturer’s instructions (QIAamp DNA Stool Mini Kit (QIAGEN)).

Three pairs of primers targeting the 16S and 23S genes were used in PCR assays for the detection and identification of arcobacters [31]. The CRY1-CRY2 primers amplified a 257-bp fragment from A. cryaerophilus, the ARCO-BUTZ a 401-bp fragment from A. butzleri, and the ARCO-SKRIR a 641-bp fragment from A. skirrowii [31]. The primers were synthesized by MWG-Biotech (Mannheim, Germany).

The amplification was performed on a PCR Sprint Thermal Cycler (Hybaid, UK), as previously described [32].

Briefly, PCR conditions provided an initial denaturation at 95°C for 15 min, followed by 35 cycles of denaturation at 94°C (1 min), annealing at 50°C (1 min), extension at 72°C (1 min), and a final extension at 72°C for 10 min. A negative control lacking the DNA template was included in each experiment. The Arcobacter strains used as positive controls in the PCR tests included A. butzleri ATCC 49616T, A. cryaerophilus ATCC 43157, and A. skirrowii ATCC 51132T. PCR products were then separated by electrophoresis on an 1.5% agarose gel, and DNA fragments were visualized by UV illumination, after staining with ethidium bromide.

A random sample of positive PCR products from both isolates (n = 3) and faecal DNA (n = 26) was confirmed by direct sequencing using primers described by Houf et al. [31] at the Genelab, ENEA, Rome (Italy).

2.6. Statistical Analysis. Statistical analysis was performed using the SPSS program, version 11.0 for Windows (SPSS Inc. Chicago, IL). Data are given as mean ± SD. We used χ² test to compare categorical measures and the analysis of variance (ANOVA) for continuous measures. Linear regression models were determined using a stepwise selection procedure for all the factors, entering the continuous variables with the use of appropriate transformations. All statistical comparisons are two-tailed, and they were considered significant at the P < .05 level.

3. Results

3.1. Clinical Characteristics of Study Population. Clinical characteristics of the study population according to the presence of type 2 diabetes are summarized in Table 1. Overall, diabetic patients were older, with an acceptable metabolic control despite the relatively long duration of diabetes. Diabetic subjects also showed significantly higher values of BMI, waist circumference, fasting blood glucose, and triglycerides and lower concentrations of total, LDL- and HDL-cholesterol as compared to nondiabetic subjects.

Infection laboratory indexes (ESR, leucocyte blood count, and percentage of neutrophils) were within the normal range, although with some differences between the two groups (Table 1).

Also the percentage of smokers was higher in diabetic versus controls (P = .05), whereas no other significant differences were noted between the two groups.

3.2. Prevalence of Arcobacter Colonization in the Study Population. Data on the prevalence of Arcobacter in the examined stool samples, as determined both by cultural and molecular techniques, are shown in Table 1.

Only 3 of the 99 cultures were positive (3%), while Arcobacter DNA was detected by PCR analysis in 46 (46.5%) stool samples including the 3 samples positive by culture that belonged to diabetic subjects. In particular, molecular evidence of Arcobacter was noted in 30 (79%) subjects with and 16 (26.2%) without type 2 diabetes (P < .001).


|                          | Type 2 diabetic subjects | Non diabetic subjects | P       |
|--------------------------|--------------------------|-----------------------|---------|
| n                        | 38                       | 61                    |         |
| Male sex n (%)           | 21 (55.3)                | 33 (54)               |         |
| Age (years)              | 63.1 ± 9.3*              | 54.3 ± 7.2            | <.0001  |
| BMI (kg/m²)              | 29.5 ± 4.3               | 27.1 ± 2.9            | .001    |
| Waist circumference (cm) | 98.3 ± 9.2               | 91.6 ± 9.8            | .001    |
| Low instruction level n (%) | 30 (78.9)             | 40 (65.6)             | —       |
| Hypertension n (%)       | 20 (52.6)                | 25 (41.0)             | —       |
| Current smokers n (%)    | 15 (39.5)                | 13 (21.3)             | .05     |
| Diabetes duration (years)| 10.9 ± 8.8               | —                     | —       |
| Fasting blood glucose (mg/dL) | 146.7 ± 49.3      | 90.8 ± 6.3            | <.0001  |
| HbA1c (%)                | 7.06 ± 1.34              | —                     |         |
| Total Cholesterol (mg/dL)| 178.5 ± 37.9             | 199.4 ± 27.0          | .001    |
| LDL-Cholesterol (mg/dL)  | 104.1 ± 41.2             | 123.6 ± 28.0          | .006    |
| HDL-Cholesterol (mg/dL)  | 48.7 ± 9.4               | 54.4 ± 10.4           | .008    |
| Triglycerides (mg/dL)    | 132.6 ± 50.2             | 110.7 ± 50.6          | .04     |
| ESR (mm/hr)              | 10.3 ± 6.1               | 12.8 ± 6.2            | .02     |
| Leukocyte Blood Count/mm³| 7317 ± 1552              | 6651 ± 1506           | .04     |
| Neutrophils (%)          | 58.6 ± 7.6               | 61.5 ± 5.6            | .04     |
| Positive cultures for Arcobacter n (%) | 3 (7.9)          | 0                     |         |
| A. butzleri n (%)        | 1 (33.3)                 | —                     |         |
| A. cryaerophilus n (%)   | 1 (33.3)                 | —                     |         |
| A. butzleri and A. cryaerophilus n (%) | 1 (33.3)         | —                     |         |
| Positive PCR for Arcobacter n (%) | 30 (78.9)       | 16 (26.2)             | .001    |
| A. butzleri n (%)        | 3 (10)                   | 2 (12.25)             |         |
| A. cryaerophilus n (%)   | 12 (40)                  | 9 (56.25)             |         |
| A. butzleri and A. cryaerophilus n (%) | 15 (50)            | 5 (31.25)             |         |

*Mean ± SD. Only significant P-values are presented.
BMI: Body mass index.
HbA1c: Glycated haemoglobin, available for diabetic subjects only.
ESR: Erythrocyte Sedimentation Rate.

Of the 3 positive cultures, the PCR analysis revealed that one was positive for *A. butzleri*, another for *A. cryaerophilus*, and the third for both *A. butzleri* and *A. cryaerophilus*.

The sequences obtained from three of our Arcobacter isolates (MTF1, MTF2, MTF3) confirmed the PCR data, showing a 100% sequence similarity with *A. butzleri* (GenBank accession no.: AY621116) for MTF1 and a 98% sequence similarity to *A. cryaerophilus* (GenBank accession no.: X80383; AB081300) for both MTF2 and MTF3.

Of the 46 Arcobacter PCR positive samples, 21 (45.6%) were positive for *A. cryaerophilus*, 20 (43.5%) for both *A. butzleri* and *A. cryaerophilus*, and 5 (10.9%) for *A. butzleri*.

Comparing the sequences of 26 PCR products, randomly selected among the 46 positive faecal DNA samples, with previously published sequences in the GenBank database, a very high degree of similarity of our sequences with *A. butzleri* (accession no.: CP000361; AY621116; EU252504) and *A. cryaerophilus* (accession no.: X80383; AB081300) was found.

Neither *A. skirrowii* isolates nor *A. skirrowii* PCR products were found in our study. Figure 1 shows a representative example of PCR analysis of DNA extracted from faecal samples.

The GenBank accession numbers for our nucleotide sequences are as follows: GU116587, GU116588 and GU116589 for the isolates MTF1, MTF2, MTF3, respectively, and from GU108194 to GU108219 for the faecal DNA sequences.

### 3.3. Clinical Differences in Diabetic and Nondiabetic Subjects, According to Arcobacter Colonization

When clinical characteristics of subjects with or without *Arcobacter* carriage were compared in the diabetic and non diabetic groups separately (Table 2), diabetic subjects with evidence of arcobacters were significantly older as compared to those without it (*P* < .001), whereas no differences were noted in the other clinical characteristics between the two groups (Table 2). Similarly, no differences were noted in diabetes-related variables, such as diabetes duration, current therapy with oral hypoglycaemic agents and/or insulin, and the rate of micro- and/or macrovascular complications between diabetic subjects with or without *Arcobacter* colonization (data not shown).
Figure 1: Example of the PCR analysis of DNA extracted from the 3 reference strains and of five representative faecal samples using the species specific primers. Lane M, 100-bp ladder; lanes 1–3 PCR products of the control strains: *A. butzleri* ATCC 49616T (401-bp), *A. cryaerophilus* ATCC 43157 (257-bp), and *A. skirrowii* ATCC 51132T (641-bp), respectively. Lanes A, F, N, and B, G, O results obtained for samples 1 and 2, respectively, showing only amplicons of the expected size for *A. cryaerophilus*; lanes C, H, P and D, I, Q, results obtained from samples 3 and 4, respectively, showing only amplicons of the expected size for *A. butzleri*; lanes E, L, R, results obtained from sample 5 showing amplicons of the expected size for *A. butzleri* and *A. cryaerophilus*. None of the samples showed amplicons with the *A. skirrowii*-specific primers; lanes 4 to 6, negative controls.

### Table 2: Clinical characteristics in diabetic and nondiabetic subjects with or without evidence of *Arcobacter* colonization.

|                      | Type 2 diabetic subjects | Non diabetic subjects |
|----------------------|--------------------------|-----------------------|
|                      | Without Arcobacter colonization | With Arcobacter colonization | Without Arcobacter colonization | With Arcobacter colonization |
| $n$                  | 8 (21.1)                 | 30 (78.9)             | 45 (73.8)             | 16 (26.2) |
| Male sex $n$ (%)     | 3 (37.5)                 | 18 (60.0)             | 24 (53.3)             | 9 (56.3)  |
| Age (years)          | 54.1 ± 8.9*              | 65.8 ± 7.8†           | 54.0 ± 7.0            | 55.9 ± 8.2 |
| BMI (kg/m²)          | 31.9 ± 6.4               | 28.8 ± 3.4            | 27.0 ± 2.8            | 27.7 ± 3.2 |
| Waist circumference (cm) | 99.4 ± 11.8             | 98.0 ± 8.7            | 90.2 ± 9.2            | 95.9 ± 10.6†† |
| Low instruction level $n$ (%) | 5 (62.5)               | 25 (83.3)             | 30 (66.6)             | 10 (62.5)  |
| Current smokers $n$ (%) | 3 (37.5)               | 12 (40.0)             | 10 (22.2)             | 3 (18.8)  |
| Dyslipidemia $n$ (%)  | 5 (62.5)                 | 22 (73.3)             | 16 (35.5)             | 5 (31.2)  |
| Hypertension $n$ (%)  | 3 (37.5)                 | 17 (56.6)             | 14 (31.1)             | 11 (68.8)† |
| Fasting blood glucose (mg/dL) | 136.5 ± 48.0           | 149.4 ± 50.1          | 90.0 ± 6.3            | 93.1 ± 5.9 |
| HbA1c (%)            | 7.2 ± 1.2                | 7.1 ± 1.3             | —                     | —         |
| Total Cholesterol (mg/dL) | 165.2 ± 42.0            | 182.0 ± 36.6          | 198.8 ± 28.2          | 201.2 ± 23.5 |
| LDL-Cholesterol (mg/dL) | 91.7 ± 35.8            | 107.4 ± 42.5          | 124.5 ± 29.6          | 119.6 ± 22.1 |
| HDL-Cholesterol (mg/dL) | 46.6 ± 8.8              | 49.3 ± 9.7            | 54.1 ± 9.6            | 55.1 ± 12.6 |
| Triglycerides (mg/dL) | 141.7 ± 42.8            | 130.2 ± 52.3          | 111.0 ± 53.6          | 109.9 ± 42.7 |

*Mean ± SD. Only significant $P$-values are presented.
†$P < .001$ versus subjects without *Arcobacter* colonization.
††$P < .05$ versus subjects without *Arcobacter* colonization.

BMI: Body mass index.
HbA1c: Glycated haemoglobin, available for diabetic subjects only.

In the non diabetic group (Table 2), carriers of arcobacters had a significantly higher waist circumference ($P = .05$) and a higher rate of hypertension ($P < .001$) as compared to noncarriers. No other significant differences in clinical characteristics were noted between the two groups.

At multivariate analysis, performed in the whole population and including in the model all the variables that showed significant differences between subjects with and without arcobacters (age, waist circumference, hypertension, and diabetes), type 2 diabetes ($\beta = 1.913; P < .0001$) and age ($\beta = 1.744; P = .001$) were confirmed as the only factors independently associated with *Arcobacter* colonization in this population, with a OR of 6.8 (95%CI: 2.378–19.285) in diabetic versus non diabetic subjects, and an OR of 5.7 (95%CI: 2.077–15.766) in older versus younger subjects.

### 4. Discussion

Although data on healthy carriers are available worldwide [14, 15, 33], our study is the first investigation on the prevalence of *Arcobacter* carriage in diabetic subjects without specific gastrointestinal symptoms in Italy.
We found that type 2 diabetes and older age were associated with an impressively high rate of Arcobacter carriage. Overall, we found a high prevalence of Arcobacter colonization with 46 positive cases by molecular analysis and 3 positive cases by cultural methods, as evaluated by both direct plating and enrichment procedures. Compared to the cultural method, the PCR analysis identified 43 more cases, namely 41.4% cases positive for A. cyaerophilus, and 25.2% for A. butzleri, thus confirming, as previously reported [32], the superiority of the molecular method over the cultural one in arcobacters detection. However, several other reasons may explain the very low detection rate for Arcobacter with cultural methods in our study, including the differences on isolation methods [17, 23, 34]. First of all, it has been indicated that CAT agar supplemented media that have been used in this study are not able to adequately inhibit other faecal microorganisms [23, 35–37], that might mask arcobacters, thus resulting in a lack of detection by cultural methods. This was clearly improved in other studies using the membrane filtration method that produced a reduction of the competitive microbiota [14, 23, 35–37]. Other authors found almost equal results between the m-PCR detection methods [31] from the enrichment Arcobacter broth supplemented with CAT, by culturing the broth after active filtration (0.45 mm membrane filters) on blood agar [23, 36].

Consistent with another study [15], we found that A. cyaerophilus was the most frequently occurring species in all the examined samples, whereas other authors have identified A. butzleri as the dominant species [1, 17].

Furthermore, our study reported, for the first time in humans, a concurrent colonization with two different Arcobacter species, namely A. butzleri and A. cyaerophilus, an occurrence that has been reported for animals [5, 38], for water and food products [23, 35]. Thus, the coexistence of two species in the same stool samples was found in a single patient with cultural method, but it was shown at higher rates by PCR (20 patients, 43.5%). The latter findings suggest the possibility of multiple sources of contaminations or the consumption of water or food products simultaneously contaminated with both species.

Epidemiological data on the occurrence of arcobacters in humans show different prevalence rates, both in asymptomatic and symptomatic subjects [1, 14, 15], especially those obtained by molecular methods [1, 33, 39]. Although our detection rate is considerably higher when compared to these studies, the prevalence obtained in our diabetic patients with no gastrointestinal disease is hardly comparable with the variable data obtained from healthy subjects, of different ages [1, 14, 15]. Furthermore, the generally low socioeconomic status of subjects participating to our study may be another issue in favouring arcobacters transmission [40], although no differences were noted in the instruction level between carriers and non carriers of these microorganisms, either in diabetic or in control subjects.

Several metabolic and nonmetabolic factors, such as age, hypertension, waist circumference, and diabetes, were all associated with arcobacters carriage in our study participants; however, in the whole study group, only type 2 diabetes and an older age were significant and independent risk factors for Arcobacter colonization in this population, with a risk that was 7- and 6-fold higher in diabetic and older subjects as compared to nondiabetic and younger ones, respectively.

The very high arcobacters carriage rate found in our diabetic patients largely confirms their generally high susceptibility to infections, related to the hyperglycaemic milieu that favours bacterial growth, as well as to an altered motility of gastroenteric tract, as a consequence of autonomic neuropathy and/or microangiopathy, or to the impaired humoral and cellular host defence [20, 24, 25].

Notably, the very high prevalence of arcobacters detected in type 2 diabetic and older patients, together with the potential decline of their immune system competency [41], may pose these subjects at higher risk of infection.

Although conducted in a small sample, our results clearly indicate that older subjects and those with type 2 diabetes are at greater risk for arcobacters carriage; large prospective studies are needed to evaluate the potential health risk associated with arcobacter colonization in these high risk groups.

Acknowledgment

This study was supported by research grants (2005 financing) from the University of Messina, Italy.

References

[1] O. Vandenbergh, A. Dediste, K. Houf, et al., “Arcobacter species in humans,” Emerging Infectious Diseases, vol. 10, no. 10, pp. 1863–1867, 2004.
[2] I. Wybo, J. Breynaert, S. Lauwers, F. Lindenburg, and K. Houf, “Isolation of Arcobacter skirrowii from a patient with chronic diarrhea,” Journal of Clinical Microbiology, vol. 42, no. 4, pp. 1851–1852, 2004.
[3] P. Vandamme, M. Vancanneyt, B. Pot, et al., “Polyphasic taxonomic study of the emended genus Arcobacter with Arcobacter butzleri comb. nov. and Arcobacter skirrowii sp. nov., an aerotolerant bacterium isolated from veterinary specimens,” International Journal of Systematic Bacteriology, vol. 42, no. 3, pp. 344–356, 1992.
[4] E. Van Driessche, K. Houf, J. Van Hoof, L. De Zutter, and P. Vandamme, “Isolation of Arcobacter species from animal feces,” FEMS Microbiology Letters, vol. 229, no. 2, pp. 243–248, 2003.
[5] E. Van Driessche, K. Houf, F. Vangroenweghe, et al., “Occurrence and strain diversity of Arcobacter species isolated from healthy Belgian pigs,” Research in Microbiology, vol. 155, no. 8, pp. 662–666, 2004.
[6] L. Rivas, N. Fegan, and P. Vanderlinde, “Isolation and characterisation of Arcobacter butzleri from meat,” International Journal of Food Microbiology, vol. 91, no. 1, pp. 31–41, 2004.
[7] C. R. McClung, D. G. Patriquin, and R. E. Davis, “Campylobacter nitrofigilis sp. nov., a nitrogen-fixing bacterium associated with roots of Spartina alterniflora Loisel.,” International Journal of Systematic Bacteriology, vol. 33, no. 3, pp. 605–612, 1983.
[8] S. P. Donachie, J. P. Bowman, S. L. W. On, and M. Alam, “Arcobacter halophilus sp. nov., the first obligate halophile in
the genus Arcobacter,” *International Journal of Systematic and Evolutionary Microbiology*, vol. 55, no. 3, pp. 1271–1277, 2005.

[9] K. Houf, S. L. W. On, T. Coenye, J. Mast, J. Van Hoof, and P. Vandamme, “*Arcobacter cibarius* sp. nov., isolated from broiler carcasses,” *International Journal of Systematic and Evolutionary Microbiology*, vol. 55, no. 2, pp. 713–717, 2005.

[10] H. M. Kim, C. Y. Hwang, and B. C. Cho, “*Arcobacter marinus* sp. nov.,” *International Journal of Systematic and Evolutionary Microbiology*, vol. 60, no. 3, pp. 531–536, 2010.

[11] K. Houf, S. L. W. On, T. Coenye, L. Debruyne, S. De Smet, and P. Vandamme, “*Arcobacter thereicus* sp. nov., isolated from pigs and ducks,” *International Journal of Systematic and Evolutionary Microbiology*, vol. 59, no. 10, pp. 2599–2604, 2009.

[12] L. Collado, I. Glennwerck, S. Van Trappen, P. De Vos, and M. J. Figueras, “*Arcobacter mytili* sp. nov., an indoxyl acetate-hydrolysis-negative bacterium isolated from mussels,” *International Journal of Systematic and Evolutionary Microbiology*, vol. 59, no. 6, pp. 1391–1396, 2009.

[13] C. O. Wirsen, S. M. Sievert, C. M. Cavanaugh, et al., “Characterization of an autotrophic sulfide-oxidizing marine *Arcobacter* sp. that produces filamentous sulfur,” *Applied and Environmental Microbiology*, vol. 68, no. 1, pp. 316–325, 2002.

[14] J. Engberg, S. L. W. On, C. S. Harrington, and P. Gerner-Smidt, “Prevalence of *Campylobacter, Arcobacter, Helicobacter*, and *Sutterella* spp. in human fecal samples as estimated by a reevaluation of isolation methods for Campylobacters,” *Journal of Clinical Microbiology*, vol. 38, no. 1, pp. 286–291, 2000.

[15] K. Houf and R. Stephan, “Isolation and characterization of the emerging foodborne pathogen *Arcobacter* from human stool,” *Journal of Microbiological Methods*, vol. 68, no. 2, pp. 408–413, 2007.

[16] J. Lerner, V. Brumberger, and V. Preac-Mursic, “Severe diarrhea associated with *Arcobacter butzleri,*” *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 13, no. 8, pp. 660–662, 1994.

[17] V. Prouzet-Mauleon, L. Labadi, N. Bouges, A. Ménard, and F. Mégraud, “*Arcobacter butzleri*: underestimated enteropathogen,” *Emerging Infectious Diseases*, vol. 12, no. 2, pp. 307–309, 2006.

[18] P. Vandamme, P. Pugina, G. Benzi, et al., “Outbreak of recurrent abdominal cramps associated with *Arcobacter butzleri* in an Italian school,” *Journal of Clinical Microbiology*, vol. 30, no. 9, pp. 2335–2337, 1992.

[19] V. Prouzet-Mauleon, L. Labadi, N. Bouges, A. Ménard, and F. Mégraud, “*Arcobacter butzleri* isolates from a traffic accident victim with bacteremia by 16S ribosomal RNA gene sequencing,” *Diagnostic Microbiology & Infectious Disease*, vol. 40, no. 3, pp. 125–127, 2001.

[20] S. K. P. Lau, P. C. Y. Woo, J. L. L. Teng, K. W. Leung, and K. Y. Yuen, “Identification by 16S ribosomal RNA gene sequencing of *Arcobacter butzleri* bacteriaemia in a patient with acute gangrenous appendicitis,” *Molecular Pathology*, vol. 55, no. 3, pp. 182–185, 2002.

[21] A. Lehner, T. Tasara, and R. Stephan, “Relevant aspects of *Arcobacter* spp. as potential foodborne pathogen,” *International Journal of Food Microbiology*, vol. 102, no. 2, pp. 127–135, 2005.

[22] C. A. Phillips, “Arcobacters as emerging human foodborne pathogens,” *Food Control*, vol. 12, no. 1, pp. 1–6, 2001.

[23] L. Collado, I. Inza, J. Guarro, and M. J. Figueras, “Presence of *Arcobacter* spp. in environmental waters correlates with high levels of fecal pollution,” *Environmental Microbiology*, vol. 10, no. 6, pp. 1635–1640, 2008.

[24] G. Perdichizzi, M. Bottari, S. Pallio, M. T. Fera, M. Carbone, and G. Barresi, “Gastric infection by *Helicobacter pylori* and antral gastritis in hyperglycemic obese and in diabetic subjects,” *New Microbiologica*, vol. 19, no. 2, pp. 149–154, 1996.

[25] A. Bener, R. Micallef, M. Afifi, M. Derbala, H. M. Al-Mulla, and M. A. Usmani, “Association between type 2 diabetes mellitus and *Helicobacter pylori* infection,” *Turkish Journal of Gastroenterology*, vol. 18, no. 4, pp. 225–229, 2007.

[26] R. Kahn, “Report of the expert committee on the diagnosis and classification of diabetes mellitus,” *Diabetes Care*, vol. 20, no. 7, pp. 1183–1197, 1997.

[27] American Diabetes Association, “Standards of medical care in diabetes—2008,” *Diabetes Care*, vol. 31, supplement 1, pp. S12–S54, 2008.

[28] C. B. Giorda, A. Avogaro, M. Maggini, et al., “Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors,” *Diabetes Care*, vol. 31, no. 11, pp. 2154–2159, 2008.

[29] A. Avogaro, C. Giorda, M. Maggini, et al., “The prevalence of coronary heart disease in type 2 diabetic patients in Italy: the DAI study,” *Diabetic Medicine*, vol. 21, no. 7, pp. 738–745, 2004.

[30] M. T. Fera, C. Gugliandolo, V. Lentini, et al., “Specific detection of *Arcobacter* spp. in estuarine waters of Southern Italy by PCR and fluorescent in situ hybridization,” *Letters in Applied Microbiology*, vol. 50, no. 1, pp. 65–70, 2010.

[31] K. Houf, A. Tutenel, L. De Zutter, J. Van Hoof, and P. Vandamme, “Development of a multiplex PCR assay for the simultaneous detection and identification of *Arcobacter butzleri*, *Arcobacter cryaerophilus* and *Arcobacter skirrowii*,” *FEMS Microbiology Letters*, vol. 193, no. 1, pp. 89–94, 2000.

[32] M. T. Fera, T. L. Maugeri, C. Gugliandolo, et al., “Detection of *Arcobacter* spp. in the coastal environment of the Mediterranean Sea,” *Applied and Environmental Microbiology*, vol. 70, no. 3, pp. 1271–1276, 2004.

[33] A. Samie, C. L. Obi, L. J. Barrett, S. M. Powell, and R. L. Guerrant, “Prevalence of *Campylobacter* species, *Helicobacter pylori* and *Arcobacter* species in stool samples from the Venda region, Limpopo, South Africa: studies using molecular diagnostic methods,” *Journal of Infection*, vol. 54, no. 6, pp. 558–566, 2007.

[34] E. Van Driessche, K. Houf, F. Vangroenweghe, L. De Zutter, and J. Van Hoof, “Prevalence, enumeration and strain variation of *Arcobacter* species in the faeces of healthy cattle in Belgium,” *Veterinary Microbiology*, vol. 105, no. 2, pp. 149–154, 2005.

[35] H. I. Atabay, M. Waino, and M. Madsen, “Detection and diversity of various *Arcobacter* species in Danish poultry,” *International Journal of Food Microbiology*, vol. 109, no. 1–2, pp. 139–145, 2006.

[36] L. Collado, I. Guarro, and M. J. Figueras, “Prevalence of *Arcobacter* in meat and shellfish,” *Journal of Food Protection*, vol. 72, no. 5, pp. 1102–1106, 2009.

[37] H. Ongör, B. Cetinkaya, M. N. Açıkk, and H. I. Atabay,
“Investigation of arcobacters in meat and faecal samples of clinically healthy cattle in Turkey,” *Letters in Applied Microbiology*, vol. 38, no. 4, pp. 339–344, 2004.

[38] M. T. Fera, E. La Camera, M. Carbone, D. Malara, and M. G. Pennisi, “Pet cats as carriers of *Arcobacter* spp. in Southern Italy,” *Journal of Applied Microbiology*, vol. 106, no. 5, pp. 1661–1666, 2009.

[39] K. Abdelbaqi, A. Buissonnière, V. Prouzet-Mauleon, et al., “Development of a real-time fluorescence resonance energy transfer PCR to detect *Arcobacter* species,” *Journal of Clinical Microbiology*, vol. 45, no. 9, pp. 3015–3021, 2007.

[40] P. Moayyedi, A. T. R. Axon, R. Feltbower, et al., “Relation of adult lifestyle and socioeconomic factors to the prevalence of *Helicobacter pylori* infection,” *International Journal of Epidemiology*, vol. 31, no. 3, pp. 624–631, 2002.

[41] A. R. De Gaudio, S. Rinaldi, C. Chelazzi, and T. Borracci, “Pathophysiology of sepsis in the elderly: clinical impact and therapeutic considerations,” *Current Drug Targets*, vol. 10, no. 1, pp. 60–70, 2009.